Acetyl-L-Carnitine in Neuropathic PainExperimental Data

被引：0
作者：
Santina Chiechio
Agata Copani
Robert W. Gereau
Ferdinando Nicoletti
机构：
[1] University of Catania,Department of Pharmaceutical Sciences
[2] IBB,Washington University Pain Center and Department of Anesthesiology
[3] CNR,Department of Human Physiology and Pharmacology
[4] Washington University School of Medicine,undefined
[5] University of Rome ‘La Sapienza’,undefined
[6] Istituto Neurologico Mediterraneo Neuromed,undefined
来源：
CNS Drugs | 2007年 / 21卷
关键词：
Neuropathic Pain; Sciatic Nerve; Dorsal Horn; Chronic Constriction Injury; mGlu2 Receptor;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Acetyl-L-carnitine (ALC) has gained clinical interest for its analgesic effect in different forms of neuropathies associated with chronic pain, such as diabetic and HIV-related peripheral neuropathies. The antinociceptive effect of ALC has been confirmed in several experimental models of neuropathic pain, including streptozotocin- and chemotherapy-induced neuropathy, and the sciatic nerve chronic constriction injury model. In these models, prophylactic administration of ALC has proven to be effective in preventing the development of neuropathic pain. In addition, ALC is known to produce a strong antinociceptive effect when given after neuropathic pain has been established. ALC can also improve the function of peripheral nerves by increasing nerve conduction velocity, reducing sensory neuronal loss, and promoting nerve regeneration.
引用
收藏
页码：31 / 38
页数：7
相关论文
共 178 条
[1]  
Bremer J(1983)Carnitine: metabolism and functions Physiol Rev 63 1420-80
[2]  
Farrell S(1986)Entry of acetyl-L-carnitine into biosynthetic pathways Biochim Biophys Acta 876 175-7
[3]  
Vogel J(2003)Crystal structure of carnitine acetyltransferase and implications for the catalytic mechanism and fatty acid transport Cell 112 113-22
[4]  
Bieber LL(2001)Functional relevance of carnitine transporter OCTN2 to brain distribution of L-carnitine and acetyl-L-carnitine across the blood-brain barrier J Neurochem 79 959-69
[5]  
Jogl G(2003)Acetyl-L-carnitine permeability across the blood-brain barrier and involvement of carnitine transporter OCTN2 Biopharm Drug Dispos 24 357-65
[6]  
Tong L(1981)Utilization of citrate, acetylcarnitine, acetate, pyruvate and glucose for the synthesis of acetylcholine in rat brain slices J Neurochem 36 1323-30
[7]  
Kido Y(2006)L-Acetylcarnitine: a proposed therapeutic agent for painful peripheral neuropathies Curr Neuropharmacol 4 233-7
[8]  
Tamai I(2004)Acetyl-1-carnitine: a pathogenesis based treatment for HIV-associated antiretroviral toxic neuropathy AIDS 18 1549-60
[9]  
Ohnari A(1997)Effect of acetyl-L-carnitine in the treatment of painful peripheral neuropathies in HIV+ patients J Peripher Nerv Syst 2 250-2
[10]  
Inano A(2002)Acetyl-L-carnitine (levacecarnine) in the treatment of diabetic neuropathy: a long-term, randomised, double-blind, placebo-controlled study Drugs R D 3 223-31
12345678910